CARETEQ (ASX:CTQ) is an Australian company with a focus on delivering best in class technology solutions for Health and Aged Care for a global audience.
Read more at careteq.com.au
Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.
Read more at antisense.com.au
PharmAust (PAA) is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs lowering the risks and costs of development.
Read more at pharmaust.com
Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections
Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia
Read more at www.islandpharmaceuticals.com
Arovella Therapeutics (ASX: ALA) is a biotechnology company focused on developing therapies to treat human disease. Our two focus areas are oncology and conditions that impact the central nervous system.
Read more at www.arovella.com
Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.
Read more at actinogen.com.au
An Australian biotechnology company focused on the development and commercialisation of its i-body technology platform that has generated a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.
Read more at adalta.com.au
A clinical-stage pharmaceutical company that is pioneering the development and commercialisation of a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic-resistant superbugs and emerging viral pathogens.
Read more at recce.com.au
Somnomed is the world’s the world’s largest supplier of oral sleep apnea devices, operating in 28 countries. Since 2004, Somnomed has successfully treated more than 700,000 patients for a good night’s sleep.
With headquarters in Sydney, Australia and offices in Europe and the United States, SomnoMed® focuses on developing and manufacturing clinically proven medical devices for the treatment of Obstructive Sleep Apnea (OSA).
To read more, visit somnomed.com